Evermine50 DES- Path Breaking Innovation in the field of cardiovascular care

Coronary artery disease is the blockage in arteries lead to the impeded blood flow and heart muscles losing
their oxygen supply and often beginning to die. Plaque buildup, if left unchecked, can cause breathlessness, heart
arrhythmia, cardiac arrest, heart failure and even death. In such cases, one of the main approaches to treat the
patient other then open heart surgery also know as Bypass surgery is through an intervention in the form of an
angioplasty. It’s a minimally invasive life-saving non-surgical procedure that results in improvement in heart
functions by restoring blood flow in coronary arteries. A stent is most often used to treat the artery blockage in
such procedures.

Evermine50™ is an Everolimus-eluting coronary stent system having an ultrathin (50 µm) strut. It is a precisely
engineered balloon mounted Cobalt-Chromium alloy device that is delivered using a catheter to the site of the
blockage in a coronary artery and then deployed by inflating the balloon. The stent, upon deployment, pushes
back the plaque or blockage radially, and then keeps the artery open to allow improved blood flow. The
Everolimus drug is slowly released from the stent and this ensures that the long term outcome of the procedure is
good. Thus the artery heals appropriately, allowing the patient to continue a healthy life.

Evermine50’s ultra-low strut thickness of just 50 µm minimizes chances of vascular injury without compromising
radial strength or visibility during deployment. This ultra-thin stent ensures that the tip entry profile is also reduced
significantly. The device has a unique hybrid cell design of open and closed cells, made of fully biocompatible
Co-Cr L605 alloy. Its unique design gives it outstanding radial strength, while the delivery platform ensures
flexibility and deliverability. The catheter has been designed specially with short balloon shoulders and a low
balloon overhang to minimize balloon related edge injury. Therefore this best-in-class product helps us push the
frontiers of cardiac healthcare solutions by bringing precise engineering to a life saving device that strikes the
perfect balance between favorable outcomes and risk minimization.

We at Meril Life have our patients’ long-term safety and health as our highest priority and therefore base our R&D
strongly on the evidence emerging from the interventional cardiology fraternity. The science has been loud and
clear on the advantages of thin struts in coronary stents. Compared to thicker struts, thin struts lead to less vessel
injury, lowered risk of inflammation and reduced chances of thrombus formation.

We used that evidence in our ethos when the world’s thinnest commercially available stent Evermine50 was
launched. We also recognized the challenges that such a thin strut stent would pose, and ensured that the
engineering process allowed us to address all challenges on radial strength and visibility. The extensive and
rigorous bench tests and clinical studies have vindicated our faith, making Evermine50 a new benchmark in the
world of angioplasties.

Meril Life Sciences is committed to alleviating human suffering and improving quality of life by manufacturing and
delivering path-breaking medical devices and healthcare products. Our innovation, design and development all
prioritize patient safety and superiority of clinical outcomes. The Evermine50™ is a testament to that very deeply
held value, and all around the world it is helping improve cardiac healthcare and enriching people’s lives.

To know more in detail visit Evermine 50 drug eluting stent